FibroBiologics announced the grant of European Patent EP3787647 for its fibroblast‑conditioned media platform, a key component of its cell‑therapy strategy for disc degeneration. The patent covers a novel fibroblast‑derived media formulation designed to support disc tissue regeneration, aligning with the company’s existing U.S. patents in the same therapeutic area.
The new patent extends FibroBiologics’ intellectual‑property portfolio across the European Economic Area, giving the company exclusive rights to the technology and reinforcing its competitive edge against MSC and autologous therapy developers. The company has built a broad portfolio of over 270 issued and pending patents, and this grant adds a critical asset in the high‑growth disc‑degeneration market.
While the specific grant date could not be independently confirmed, the announcement itself signals a milestone in the company’s commercialization roadmap. The patent’s subject matter is consistent with FibroBiologics’ U.S. Patent 11,732,239, which covers similar fibroblast‑conditioned media for disc degeneration, underscoring the company’s focus on fibroblast‑based therapies.
The grant is expected to strengthen FibroBiologics’ market position by protecting its proprietary media formulation from competitors and providing a defensible technology platform that can be leveraged in future product development and licensing opportunities.
The company’s strategy of building a robust IP portfolio is a core pillar of its long‑term growth plan, and the European patent adds a valuable asset that could support future clinical trials, regulatory submissions, and potential commercial partnerships in the European market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.